Otonomy, Inc. (OTIC) |
|
0.1071 -0.006 (-4.97%)
|
11-28 16:00 |
|
Open: |
0.1145 |
Pre. Close: |
0.1127 |
|
High:
|
0.1145 |
Low:
|
0.092 |
|
Volume:
|
6,480,731 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2022-11-28 4:42:08 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 0.13  One year: 0.17 |
| Support: |
Support1: 0.07 Support2: 0.05 |
| Resistance: |
Resistance1: 0.11 Resistance2: 0.14 |
| Pivot: |
0.1  |
| Moving Average: |
MA(5): 0.1 MA(20): 0.09
MA(100): 0.53 MA(250): 1.47 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 52 %D(3): 44.4 |
| RSI: |
RSI(14): 43.5 |
| 52-week: |
High: 2.58 Low: 0.07 |
| Average Vol(K): |
3-Month: 3,196 (K) 10-Days: 9,133 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OTIC ] has closed below upper band by 39.0%. Bollinger Bands are 88.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 69 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.11 - 0.12 |
0.12 - 0.12 |
|
Low:
|
0.09 - 0.09 |
0.09 - 0.09 |
|
Close:
|
0.11 - 0.11 |
0.11 - 0.11 |
|
Company Description |
|
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California. |
Headline News |
Sun, 27 Nov 2022
Solutions are Available to Save the Planet: How do we get the Public to Demand them? - Lynxotic
Fri, 25 Nov 2022
Why Elon Musk Bought Twitter V3: The Tesla Phone Wrinkle - Lynxotic
Tue, 22 Nov 2022
Do Analysts Expect Otonomy Inc (OTIC) Stock to Rise After It Is Lower By -10.00% in a Month? - InvestorsObserver
Tue, 22 Nov 2022
Goodbye Twitter, Hello Mastodon! - Lynxotic
Fri, 18 Nov 2022
Is Otonomy Inc (OTIC) Stock a Attractive Value? - InvestorsObserver
Thu, 10 Nov 2022
Otonomy GAAP EPS of -$0.18 (NASDAQ:OTIC) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
57 (M) |
| Shares Float |
38 (M) |
|
% Held by Insiders
|
2 (%) |
|
% Held by Institutions
|
36.2 (%) |
|
Shares Short
|
257 (K) |
|
Shares Short P.Month
|
694 (K) |
Stock Financials |
|
EPS
|
-0.78 |
|
EPS Est Next Qtl
|
-0.69 |
|
EPS Est This Year
|
-3.24 |
|
EPS Est Next Year
|
-2.31 |
|
Book Value (p.s.)
|
0.37 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-39.2 |
|
Return on Equity (ttm)
|
-118.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.01 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.88 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-47 (M) |
|
Levered Free Cash Flow
|
-27 (M) |
Stock Valuations |
|
PE Ratio
|
-0.14 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.28 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.14 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
